Oslo, Norway, 3 December 2020: Reference is made to the stock exchange
release<br />
by Photocure ASA ("Photocure" or the "Company") published on 1 December 2020<br
/>
regarding a share capital increase following the exercise of share options.<br
/>
<br />
The issuance of 90,150 new shares has been registered with the Norwegian<br />
Register of Business Enterprises. Following registration, the share capital
of<br />
Photocure is NOK 13,358,768 divided into 26,358,536 shares, each with a par<br
/>
value of NOK 0.50. Each share represents one vote in the Company's general<br />
meeting.<br />
<br />
For further information, please contact:<br />
<br />
Photocure<br />
CFO Erik Dahl<br />
Tel: +47 450 55 000<br />
Email: ed@photocure.com<br />
<br />
About Photocure ASA<br />
<br />
Photocure: The Bladder Cancer Company delivers transformative solutions to<br />
improve the lives of bladder cancer patients. Our unique technology, which
makes<br />
cancer cells glow bright pink, has led to better health outcomes for patients<br
/>
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo<br
/>
Stock Exchange (OSE: PHO). For more information, please visit us at<br />
www.photocure.com, www.hexvix.com or www.cysview.com<br />
<br />
All trademarks mentioned in this release are protected by law and are
registered<br />
trademarks of Photocure ASA.<br />
<br />
This information is subject to the disclosure requirements pursuant to
sections<br />
5-12 of the Norwegian Securities Trading Act.